Home > Publications database > The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. > print

001     165825
005     20240229123210.0
024 7 _ |a 10.3390/cancers12113254
|2 doi
024 7 _ |a pmid:33158149
|2 pmid
024 7 _ |a altmetric:95273529
|2 altmetric
037 _ _ |a DKFZ-2020-02405
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Brandão, Andreia
|0 0000-0003-0938-1543
|b 0
245 _ _ |a The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor.
260 _ _ |a Basel
|c 2020
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1604917490_25264
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The identification of recurrent founder variants in cancer predisposing genes may have important implications for implementing cost-effective targeted genetic screening strategies. In this study, we evaluated the prevalence and relative risk of the CHEK2 recurrent variant c.349A>G in a series of 462 Portuguese patients with early-onset and/or familial/hereditary prostate cancer (PrCa), as well as in the large multicentre PRACTICAL case-control study comprising 55,162 prostate cancer cases and 36,147 controls. Additionally, we investigated the potential shared ancestry of the carriers by performing identity-by-descent, haplotype and age estimation analyses using high-density SNP data from 70 variant carriers belonging to 11 different populations included in the PRACTICAL consortium. The CHEK2 missense variant c.349A>G was found significantly associated with an increased risk for PrCa (OR 1.9; 95% CI: 1.1-3.2). A shared haplotype flanking the variant in all carriers was identified, strongly suggesting a common founder of European origin. Additionally, using two independent statistical algorithms, implemented by DMLE+2.3 and ESTIAGE, we were able to estimate the age of the variant between 2300 and 3125 years. By extending the haplotype analysis to 14 additional carrier families, a shared core haplotype was revealed among all carriers matching the conserved region previously identified in the high-density SNP analysis. These findings are consistent with CHEK2 c.349A>G being a founder variant associated with increased PrCa risk, suggesting its potential usefulness for cost-effective targeted genetic screening in PrCa families.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Paulo, Paula
|b 1
700 1 _ |a Maia, Sofia
|b 2
700 1 _ |a Pinheiro, Manuela
|b 3
700 1 _ |a Peixoto, Ana
|b 4
700 1 _ |a Cardoso, Marta
|b 5
700 1 _ |a Silva, Maria P
|b 6
700 1 _ |a Santos, Catarina
|b 7
700 1 _ |a Eeles, Rosalind A
|0 0000-0002-3698-6241
|b 8
700 1 _ |a Kote-Jarai, Zsofia
|b 9
700 1 _ |a Muir, Kenneth
|0 0000-0001-6429-988X
|b 10
700 1 _ |a Ukgpcs Collaborators
|b 11
700 1 _ |a Schleutker, Johanna
|0 0000-0002-1863-0305
|b 12
700 1 _ |a Wang, Ying
|0 0000-0002-1241-6252
|b 13
700 1 _ |a Pashayan, Nora
|0 0000-0003-0843-2468
|b 14
700 1 _ |a Batra, Jyotsna
|b 15
700 1 _ |a Apcb BioResource
|b 16
700 1 _ |a Grönberg, Henrik
|b 17
700 1 _ |a Neal, David E
|b 18
700 1 _ |a Nordestgaard, Børge G
|0 0000-0002-1954-7220
|b 19
700 1 _ |a Tangen, Catherine M
|b 20
700 1 _ |a Southey, Melissa C
|b 21
700 1 _ |a Wolk, Alicja
|b 22
700 1 _ |a Albanes, Demetrius
|b 23
700 1 _ |a Haiman, Christopher A
|b 24
700 1 _ |a Travis, Ruth C
|b 25
700 1 _ |a Stanford, Janet L
|b 26
700 1 _ |a Mucci, Lorelei A
|b 27
700 1 _ |a West, Catharine M L
|b 28
700 1 _ |a Nielsen, Sune F
|b 29
700 1 _ |a Kibel, Adam S
|b 30
700 1 _ |a Cussenot, Olivier
|b 31
700 1 _ |a Berndt, Sonja I
|b 32
700 1 _ |a Koutros, Stella
|b 33
700 1 _ |a Sørensen, Karina Dalsgaard
|0 0000-0002-4902-5490
|b 34
700 1 _ |a Cybulski, Cezary
|0 0000-0002-2819-3057
|b 35
700 1 _ |a Grindedal, Eli Marie
|b 36
700 1 _ |a Park, Jong Y
|b 37
700 1 _ |a Ingles, Sue A
|b 38
700 1 _ |a Maier, Christiane
|b 39
700 1 _ |a Hamilton, Robert J
|b 40
700 1 _ |a Rosenstein, Barry S
|b 41
700 1 _ |a Vega, Ana
|b 42
700 1 _ |a The Impact Study Steering Committee And Collaborators
|b 43
700 1 _ |a Kogevinas, Manolis
|b 44
700 1 _ |a Wiklund, Fredrik
|0 0000-0002-4623-0544
|b 45
700 1 _ |a Penney, Kathryn L
|b 46
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 47
|u dkfz
700 1 _ |a John, Esther M
|b 48
700 1 _ |a Kaneva, Radka
|b 49
700 1 _ |a Logothetis, Christopher J
|b 50
700 1 _ |a Neuhausen, Susan L
|b 51
700 1 _ |a Ruyck, Kim De
|b 52
700 1 _ |a Razack, Azad
|b 53
700 1 _ |a Newcomb, Lisa F
|b 54
700 1 _ |a Canary Pass Investigators
|b 55
700 1 _ |a Lessel, Davor
|0 0000-0003-4496-244X
|b 56
700 1 _ |a Usmani, Nawaid
|b 57
700 1 _ |a Claessens, Frank
|b 58
700 1 _ |a Gago-Dominguez, Manuela
|0 0000-0001-6713-4351
|b 59
700 1 _ |a Townsend, Paul A
|b 60
700 1 _ |a Roobol, Monique J
|0 0000-0001-6967-1708
|b 61
700 1 _ |a The Profile Study Steering Committee
|b 62
700 1 _ |a The Practical Consortium
|b 63
700 1 _ |a Teixeira, Manuel R
|0 0000-0002-4896-5982
|b 64
773 _ _ |a 10.3390/cancers12113254
|g Vol. 12, no. 11, p. 3254 -
|0 PERI:(DE-600)2527080-1
|n 11
|p 3254
|t Cancers
|v 12
|y 2020
|x 2072-6694
909 C O |o oai:inrepo02.dkfz.de:165825
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 47
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2020
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCERS : 2018
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2020-09-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2020-09-11
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2020-09-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-09-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-09-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCERS : 2018
|d 2020-09-11
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2020-09-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2020-09-11
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 1
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21